Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nab-paclitaxel
Nab paclitaxel · 1 trial · 1 indication
Objective Response Rate (ORR): Complete Response (CR) + Partial Response (PR) according to RECIST 1.1 criteria
| Arm | Type | Description |
|---|---|---|
| Investigational treatment | EXPERIMENTAL | Conventional Chemotherapy (Gemcitabine + nab-paclitaxel) plus NLM-001 plus Zalifrelimab |
| Name | Type | Description |
|---|---|---|
| Gemcitabine | DRUG | Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy). |
| Nab paclitaxel | DRUG | Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy). |
| NLM-001 | DRUG | NLM-001 will be administered three cycles consecutively followed by two rest cycles. |
| Zalifrelimab | DRUG | Zalifrelimab administration each 6 weeks. |
Inclusion Criteria: 1. Investigators must ensure that patients are able to understand the requirements of the study and provide informed consent 2. Age ≥18 years 3. Histological or cytological diagnosis of pancreatic adenocarcinoma 4. Stage IV disease 5. No prior treatment for advanced disease. Pat...
Nab paclitaxel is being studied for the treatment of Pancreatic Ductal Adenocarcinoma. It is an investigational small molecule in Phase 1 clinical development. The drug is being evaluated in combination with standard chemotherapy plus zalifrelimab in patients with advanced pancreatic cancer.
Nab paclitaxel is being developed by Agenus Inc., a biopharmaceutical company traded on the NASDAQ under the ticker AGEN. The company is conducting clinical trials to evaluate the safety and efficacy of the drug in patients with advanced pancreatic cancer.
Nab paclitaxel is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is active but not recruiting participants, with a planned enrollment of 28 patients.
Nab paclitaxel is being studied in a Phase 1 clinical trial with the identifier NCT04827953. The trial is titled "Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer." The study is active but not recruiting and is being conducted in Spain.
Yes, Nab paclitaxel is also known as Nab-paclitaxel. Both names refer to the same drug being developed by Agenus Inc. for the treatment of Pancreatic Ductal Adenocarcinoma. The drug is currently in Phase 1 clinical trials.